The mission of the University of Minnesota Cancer Center (UMCC) Clinical Protocol and Data Management Shared Resource (hereafter referred to;as the Clinical Trials Office [CTO]) is to provide a resource to UMCC investigators allowing them to perform high quality clinical research that insures validity and integrity of data and fulfills all NCI, federal, and local regulatory requirements. The CTO's centralized services enable the investigator to initiate and participate in a wider spectrum of clinical research activities, with the primary focus on supporting the development of investigator-initiated novel therapeutic strategies that arise out of the various UMCC research programs. In addition, the CTO is a center of excellence for clinical trial planning, execution and training. The CTO provides a centralized location for the development, administration and conduct all cancer protocols including investigator initiated IND/IDE trials and all related correspondences with regulatory agencies including the University of Minnesota Institutional Review Board (IRB), National Institutes of Health (NIH) and U.S. Food and Drug Administration (FDA). The Clinical Trial Office provides four major distinct functions: 1) Clinical Trial Operations and Management, 2) Regulatory Affairs 3) Quality Control/Assurance 4) Systems Management and Resources. In conjunction with the principal investigator the CTO staff channel the development of a new clinical trial from protocol design, protocol review and approval, research staff education, study implementation, data collection and entry, through trial completion. The CTO supports investigator-initiated therapeutic and non-therapeutic studies which may be sponsored by the NCI, NHLBI or other NIH branches, in addition to cooperative group and industry studies. From September 1, 2006 to August 31,2007, more than 300 clinical trials were registered with the CTO and open to patient accrual. Of these, 29% were investigator initiated institutional trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA077598-16
Application #
8633130
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-06-01
Project End
2019-01-31
Budget Start
2014-03-05
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$407,060
Indirect Cost
$61,605
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Xu, Bin; Magli, Alessandro; Anugrah, Yoska et al. (2018) Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy. Biomaterials 183:54-66
Nikodemova, Maria; Yee, Jeremiah; Carney, Patrick R et al. (2018) Transcriptional differences between smokers and non-smokers and variance by obesity as a risk factor for human sensitivity to environmental exposures. Environ Int 113:249-258
Rashidi, Armin; Shanley, Ryan; Anasetti, Claudio et al. (2018) Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplant :
Lin, Lifeng; Chu, Haitao (2018) Bayesian multivariate meta-analysis of multiple factors. Res Synth Methods 9:261-272
Mondragon-Gonzalez, Ricardo; Perlingeiro, Rita C R (2018) Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery. Dis Model Mech 11:
Kim, J-H; Frantz, A M; Sarver, A L et al. (2018) Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Vet Comp Oncol 16:E176-E184
Jin, Jin; Zhang, Lin; Leng, Ethan et al. (2018) Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate. Stat Med 37:3214-3229
Pierpont, Elizabeth I; Hudock, Rebekah L; Foy, Allison M et al. (2018) Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1. J Neurodev Disord 10:21
Carlson, Erik S; Upadhyaya, Pramod; Villalta, Peter W et al. (2018) Analysis and Identification of 2'-Deoxyadenosine-Derived Adducts in Lung and Liver DNA of F-344 Rats Treated with the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of its Metabolite 4-(Methylnitrosamino)-1-(3-p Chem Res Toxicol 31:358-370
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267

Showing the most recent 10 out of 1013 publications